Lanthanum Carbonate

CHEMBL2096647 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
457.8 g/mol
LogP
Phase
4

A phosphate binder for dialysis patients with high phosphate levels.

الوزن الجزيئي

457,8400 g/mol

TPSA

190,00 Ų

المجالات العلاجية

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[La+3].[La+3]

InChI

InChI=1S/3CH2O3.2La/c3*2-1(3)4;;/h3*(H2,2,3,4);;/q;;;2*+3/p-6

Molecular Formula

C3La2O9

HBD / HBA

- / 9

الروابط القابلة للدوران

0

الذرات الثقيلة

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A phosphate binder for dialysis patients with high phosphate levels.

Yes, Lanthanum Carbonate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2096647. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 168924. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.